REVEAL GENOMICS FIRMA UN ACUERDO PARA SER ADQUIRIDA POR HOLOGIC PARA IMPULSAR LA MEDICINA DE PRECISIÓN EN CÁNCER DE MAMA
REVEAL GENOMICS SIGNA UN ACORD PER SER ADQUIRIDA PER HOLOGIC PER IMPULSAR LA MEDICINA DE PRECISIÓ EN EL CÀNCER DE MAMA
REVEAL GENOMICS SHAREHOLDERS ENTER INTO AN AGREEMENT FOR IT TO BE ACQUIRED BY HOLOGIC TO ADVANCE PRECISION MEDICINE IN BREAST CANCER
LARGEST PROSPECTIVE TRIAL OF 12-WEEK NEOADJUVANT TAXANE PLUS DUAL HER2 BLOCKADE CONFIRMS HER2DX PREDICTS RESPONSE IN HER2-POSITIVE BREAST CANCER
NEW ESMO OPEN REVIEW EXAMINES GROWING BODY OF EVIDENCE SUPPORTING HER2DX IN EARLY-STAGE HER2-POSITIVE BREAST CANCER
STUDY LINKS REVEAL GENOMICS ASSAYS HER2DX AND DNADX TO RESPONSE TO TRASTUZUMAB DERUXTECAN IN METASTATIC BREAST CANCER
REVEAL GENOMICS aligns founder leadership with priorities to support long-term growth, scientific excellence, and global partnerships
SABCS 2025: REVEAL GENOMICS PRESENTS MAJOR ADVANCE IN PREDICTING BRAIN METASTASIS IN HER2+ BREAST CANCER
REVEAL GENOMICS I AVANÇSA SIGNEN UN ACORD ESTRATÈGIC PER IMPULSAR EL CREIXEMENT I LA INTERNACIONALITZACIÓ DE LA COMPANYIA
NATURE COMMUNICATIONS STUDY SUPPORTS HER2DX AS A GENOMIC TOOL FOR TAILORED THERAPY IN OLDER INDIVIDUALS WITH HER2+ BREAST CANCER
REVEAL GENOMICS ACHIEVES ISO 13485:2016 CERTIFICATION FOR ITS QUALITY MANAGEMENT SYSTEM
Meta-Analysis in The Lancet Oncology Validates HER2DX Prognostic Value in Early HER2-Positive Breast Cancer
ASCO 2025: REVEAL GENOMICS UNVEILS NEW HER2DX DATA FROM 800+ PATIENTS
REVEAL GENOMICS AND ONA THERAPEUTICS JOIN FORCES TO ADVANCE NEXT-GENERATION CANCER TREATMENT
GROUNDBREAKING STUDY CONFIRMS CLINICAL DECISION IMPACT OF HER2DX® GENOMIC ASSAY IN EARLY-STAGE HER2-POSITIVE BREAST CANCER
REVEAL GENOMICS® Links Immune Tumor Response to Longevity in Breast Cancer Survivors
REVEAL GENOMICS® and the Istituto Europeo di Oncologia (IEO) Collaborate on a Groundbreaking HER2DX® Test Decision Impact Study
REVEAL GENOMICS® Unveils TNBCDX®: the First Genomic Test Designed for Early-stage Triple-Negative Breast Cancer
REVEAL GENOMICS® Announces Positive Top-Line Results For HER2DX® in CLEOPATRA Phase III Trial
Reveal Genomics® HER2DX® Genomic Test Demonstrates Significant Potential in HER2-Positive Advanced Gastric Cancer
REVEAL GENOMICS® to evaluate prospective real-time performance of HER2DX® genomic test in the United States
REVEAL GENOMICS® HER2DX® Genomic Test to be validated in Pivotal ECOG-ACRIN COMPASSHER2 pCR TRIAL in HER2+ breast cancer
REVEAL GENOMICS® HER2DX® Genomic Test to undergo first prospective trial as part of the DEFINITIVE project, funded by the European Commission
Our CSO and co-founder, Dr. Aleix Prat has been awarded the National Research Award "Doctores Diz Pintado" for his work
SABCS23: REVEAL GENOMICS® UNLEASHES GROUNDBREAKING DNADX® LIQUID BIOPSY DATA FOR METASTATIC BREAST CANCER
REVEAL GENOMICS® anuncia la inclusión de su test HER2DX® en las guías clinicas SEOM para cáncer de mama HER2+ en estadios iniciales
REVEAL GENOMICS® Announces Positive Top-Line Results FOR HER2DX® in MEDSIR’S PHERGAIN Trial
REVEAL GENOMICS®´ breakthrough technology enters the liquid biopsy field in Oncology
REVEAL GENOMICS presents the latest HER2DX® data in HER2+ breast cancer at SABCS 2022
HER2DX® recognized by TIME as one of the Best Inventions of 2022
REVEAL GENOMICS® announces positive top-line results for HER2DX® in APT and ATEMPT trials
First clinical impact data of HER2DX® according to two independent studies presented at the SEOM congress
Primeros datos de impacto clínico del HER2DX®️ según dos estudios independientes presentados en el Congreso de la SEOM
Strategic partnership between MEDSIR and REVEAL GENOMICS® for cancer research
Alianza estratégica entre MEDSIR y REVEAL GENOMICS® para investigar contra el cáncer
ESMO 2022: REVEAL GENOMICS®️ presents new validation data of HER2DX®️ in the PerELISA trial
Reveal Genomics y HM Hospitales firman un acuerdo para ofrecer el test genómico HER2DX®️ en su portfolio
Reveal Genomics Announces Research Collaboration in HER2+ Breast Cancer
REVEAL GENOMICS® Markets HER2DX®, The World's First Genomic Test for Personalized HER2+ Breast Cancer Treatment
HER2DX: First genomic test for personalized HER2+ breast cancer treatments
REVEAL GENOMICS APPOINTS PATRICIA VILLAGRASA-GONZÁLEZ CHIEF EXECUTIVE OFFICER
SPIN OFF-REVEAL GENOMICS EMERGES TO DEVELOP INNOVATIVE DIAGNOSTICS TESTS IN ONCOLOGY
